Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
Purpose
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Condition
- Heart Failure
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patient provides written authorization and/or consent per institution and geographical requirements 2. Male or non-pregnant female, aged 18 or older 3. Left ventricular ejection fraction of 25-45% (inclusive, per site assessment) 4. NYHA Class III heart failure symptoms 5. Stated willingness to comply with all study procedures and availability for the duration of the study 6. Patient has been treated with guideline-directed medical therapy
Exclusion Criteria
- Primary heart failure due to uncorrected mitral valve disease, or mitral valve repair or clip within 90 days of implant 2. IV inotropes, hemofiltration, or any form of positive inotropic support within 30 days prior to implant 3. Myocardial infarction within 90 days prior to implant 4. Undergone a CABG procedure within 90 days or a PTCA procedure within 30 days of implant 5. Prior heart transplant or ventricular assist device 6. Mechanical tricuspid valve 7. Receiving cardiac resynchronization therapy (CRT) or has a Class I indication for CRT implantation according to the ACCF/AHA/HRS guidelines for device-based therapy 8. Participating in a cardiac investigational study at the same time 9. Patient is in a vulnerable population (such as significant mental disability, prisoner) that in the judgement of the PI impedes ability to provide informed consent.
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Other
- Time Perspective
- Prospective
Recruiting Locations
Mesa, Arizona 85206
Mesa, Arizona 85206
Mesa, Arizona 85206
Phoenix, Arizona 85006
Phoenix, Arizona 85006
Phoenix, Arizona 85016
Scottsdale, Arizona 85258
Tucson, Arizona 85712
Tucson, Arizona 85724
Chula Vista, California 91911
Fairfield, California 94533
Fresno, California 93720
Los Angeles, California 90033
Los Angeles, California 90048
Northridge, California 91325
Pasadena, California 91105
Torrance, California 90505
Aurora, Colorado 80012
Jacksonville, Florida 32216
Plantation, Florida 33324
Rome, Georgia 30165
Peoria, Illinois 61614
Rockford, Illinois 61107
Urbana, Illinois 61801
Indianapolis, Indiana 46237
Indianapolis, Indiana 46260
Munster, Indiana 46321
Lexington, Kentucky 40503
Lexington, Kentucky 40536
Boston, Massachusetts 02241
Novi, Michigan 38374
Southgate, Michigan 48195
Ypsilanti, Michigan 48197
Minneapolis, Minnesota 55407
Bridgeton, Missouri 63044
Haddon Heights, New Jersey 08035
Marlton, New Jersey 08053
Morristown, New Jersey 07960
Newark, New Jersey 07719
Ridgewood, New Jersey 07450
New York, New York 10025
Asheville, North Carolina 28801
Charlotte, North Carolina 28204
Raleigh, North Carolina 27607
Cincinnati, Ohio 45242
Cleveland, Ohio 44106
Columbus, Ohio 43210
Steubenville, Ohio 43952
Toledo, Ohio 43606
Toledo, Ohio 43608
Oklahoma City, Oklahoma 73120
Allentown, Pennsylvania 18104
Bryn Mawr, Pennsylvania 19010
Harrisburg, Pennsylvania 17011
Hershey, Pennsylvania 17033
Lancaster, Pennsylvania 17602
Philadelphia, Pennsylvania 19067
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19140
Philadelphia, Pennsylvania 19141
Pittsburgh, Pennsylvania 15212
Pittsburgh, Pennsylvania 15213
Reading, Pennsylvania 19611
Yardley, Pennsylvania 19067
Austin, Texas 78705
Dallas, Texas 75216
El Paso, Texas 79915
Houston, Texas 77030
San Antonio, Texas 78229
Tyler, Texas 75702
Lynchburg, Virginia 24501
Midlothian, Virginia 23114
Richmond, Virginia 23225
Richmond, Virginia 23249
Huntington, West Virginia 25701
Milwaukee, Wisconsin 53215
More Details
- NCT ID
- NCT03970343
- Status
- Recruiting
- Sponsor
- Impulse Dynamics
Detailed Description
The Impulse Dynamics OPTIMIZER Smart Pre-Market Application (PMA) clinical data confirmed that CCM therapy delivered with the Optimizer meaningfully improved health outcomes in patients with NYHA class III heart failure symptoms and left ventricular ejection fraction of 25-45%. CCM has shown significant improvements in quality of life measures, with an average improvement of >11 points in MLHWFQ incremental to the improvement of a randomized control group with no device. Six minute hall walk and functional class also showed improvements in the PMA data. The post-approval study (PAS) protocol has been designed to evaluate long term safety and efficacy of the OPTIMIZER Smart in a real-world setting.